Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study
Identifieur interne : 002C68 ( Main/Exploration ); précédent : 002C67; suivant : 002C69Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study
Auteurs : M. Péchevis [France] ; C. E. Clarke [Royaume-Uni] ; P. Vieregge [Allemagne] ; B. Khoshnood [France] ; C. Deschaseaux-Voinet [France] ; G. Berdeaux [France] ; M. Ziegler [France]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2005-12.
English descriptors
- KwdEn :
- Activities of Daily Living, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (economics), Depression (epidemiology), Depression (etiology), Dyskinesias (economics), Dyskinesias (etiology), Dyskinesias (psychology), Europe, Female, Health Care Costs, Humans, Levodopa (adverse effects), Levodopa (economics), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (economics), Parkinson Disease (psychology), Parkinson's disease, Quality of Life, dyskinesias, health care costs, quality of life.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , economics : Antiparkinson Agents, Levodopa.
- geographic : Europe.
- drug therapy : Parkinson Disease.
- economics : Dyskinesias, Parkinson Disease.
- epidemiology : Depression.
- etiology : Depression, Dyskinesias.
- psychology : Dyskinesias, Parkinson Disease.
- Activities of Daily Living, Aged, Female, Health Care Costs, Humans, Male, Middle Aged, Quality of Life.
Abstract
The treatment of Parkinson's disease (PD) with l‐DOPA leads to involuntary movements (dyskinesias). This 6‐month observational study in three European countries in PD patients with various degrees of motor complications examined the effects of dyskinesias on the quality of life (QoL) of patients and health care costs. Retrospective and prospective health economic data were collected, and QoL of patients was measured using the Short Form‐36 (SF‐36) and the PD Quality of Life (PDQL) Scale. Regression analysis was used to estimate the adjusted effects of dyskinesias on QoL and costs, whilst accounting for the potentially confounding effects of disease progression, motor fluctuations and country. Increasing dyskinesia scores on either the Unified PD Rating Scale or the Goetz Dyskinesia Rating Scale were associated with significant reductions in QoL scores on the SF‐36 and PDQL Scale. Increasing dyskinesia severity was also associated with increased depression scores on the Montgomery–Asberg Depression Rating Scale along with significant increases in health care costs. The effects of dyskinesia on QoL, depression and costs decreased but remained significant after adjustment for the confounding effects of disease progression and motor fluctuations. In conclusion, dyskinesias may adversely affect QoL and increase health care costs in patients with PD. Future studies should evaluate the potentially beneficial effects in terms of QoL and health care costs of strategies to delay the onset of, or the treatment of, dyskinesias.
Url:
DOI: 10.1111/j.1468-1331.2005.01096.x
Affiliations:
- Allemagne, France, Royaume-Uni
- Angleterre, Midlands de l'Ouest, Région Bretagne, Île-de-France
- Birmingham, Paris, Vannes
- Université de Birmingham
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001A54
- to stream Istex, to step Curation: 001A52
- to stream Istex, to step Checkpoint: 000B31
- to stream PubMed, to step Corpus: 000F15
- to stream PubMed, to step Curation: 000E75
- to stream PubMed, to step Checkpoint: 000E75
- to stream Ncbi, to step Merge: 000569
- to stream Ncbi, to step Curation: 000569
- to stream Ncbi, to step Checkpoint: 000569
- to stream Main, to step Merge: 003039
- to stream Main, to step Curation: 002C68
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study</title>
<author><name sortKey="Pechevis, M" sort="Pechevis, M" uniqKey="Pechevis M" first="M." last="Péchevis">M. Péchevis</name>
</author>
<author><name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C. E." last="Clarke">C. E. Clarke</name>
</author>
<author><name sortKey="Vieregge, P" sort="Vieregge, P" uniqKey="Vieregge P" first="P." last="Vieregge">P. Vieregge</name>
</author>
<author><name sortKey="Khoshnood, B" sort="Khoshnood, B" uniqKey="Khoshnood B" first="B." last="Khoshnood">B. Khoshnood</name>
</author>
<author><name sortKey="Deschaseaux Oinet, C" sort="Deschaseaux Oinet, C" uniqKey="Deschaseaux Oinet C" first="C." last="Deschaseaux-Voinet">C. Deschaseaux-Voinet</name>
</author>
<author><name sortKey="Berdeaux, G" sort="Berdeaux, G" uniqKey="Berdeaux G" first="G." last="Berdeaux">G. Berdeaux</name>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:149E5B3B259D07A88201CEC980E15039BAEE6548</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1111/j.1468-1331.2005.01096.x</idno>
<idno type="url">https://api.istex.fr/document/149E5B3B259D07A88201CEC980E15039BAEE6548/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001A54</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001A54</idno>
<idno type="wicri:Area/Istex/Curation">001A52</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B31</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B31</idno>
<idno type="wicri:doubleKey">1351-5101:2005:Pechevis M:effects:of:dyskinesias</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16324089</idno>
<idno type="wicri:Area/PubMed/Corpus">000F15</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F15</idno>
<idno type="wicri:Area/PubMed/Curation">000E75</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E75</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000E75</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E75</idno>
<idno type="wicri:Area/Ncbi/Merge">000569</idno>
<idno type="wicri:Area/Ncbi/Curation">000569</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000569</idno>
<idno type="wicri:doubleKey">1351-5101:2005:Pechevis M:effects:of:dyskinesias</idno>
<idno type="wicri:Area/Main/Merge">003039</idno>
<idno type="wicri:Area/Main/Curation">002C68</idno>
<idno type="wicri:Area/Main/Exploration">002C68</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study</title>
<author><name sortKey="Pechevis, M" sort="Pechevis, M" uniqKey="Pechevis M" first="M." last="Péchevis">M. Péchevis</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMKA‐EVAL, Bourg‐la‐Reine</wicri:regionArea>
<wicri:noRegion>Bourg‐la‐Reine</wicri:noRegion>
<wicri:noRegion>Bourg‐la‐Reine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C. E." last="Clarke">C. E. Clarke</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, City Hospital NHS Trust, and University of Birmingham, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
<orgName type="university">Université de Birmingham</orgName>
</affiliation>
</author>
<author><name sortKey="Vieregge, P" sort="Vieregge, P" uniqKey="Vieregge P" first="P." last="Vieregge">P. Vieregge</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Klinikum Lippe, Lemgo</wicri:regionArea>
<wicri:noRegion>Lemgo</wicri:noRegion>
<wicri:noRegion>Lemgo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khoshnood, B" sort="Khoshnood, B" uniqKey="Khoshnood B" first="B." last="Khoshnood">B. Khoshnood</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMKA‐EVAL, Bourg‐la‐Reine</wicri:regionArea>
<wicri:noRegion>Bourg‐la‐Reine</wicri:noRegion>
<wicri:noRegion>Bourg‐la‐Reine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Deschaseaux Oinet, C" sort="Deschaseaux Oinet, C" uniqKey="Deschaseaux Oinet C" first="C." last="Deschaseaux-Voinet">C. Deschaseaux-Voinet</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>CEMKA‐EVAL, Bourg‐la‐Reine</wicri:regionArea>
<wicri:noRegion>Bourg‐la‐Reine</wicri:noRegion>
<wicri:noRegion>Bourg‐la‐Reine</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Berdeaux, G" sort="Berdeaux, G" uniqKey="Berdeaux G" first="G." last="Berdeaux">G. Berdeaux</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Université de Bretagne‐Sud, Vannes</wicri:regionArea>
<placeName><region type="region">Région Bretagne</region>
<region type="old region">Région Bretagne</region>
<settlement type="city">Vannes</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Léopold Bellan, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">European Journal of Neurology</title>
<idno type="ISSN">1351-5101</idno>
<idno type="eISSN">1468-1331</idno>
<imprint><publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2005-12">2005-12</date>
<biblScope unit="volume">12</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="956">956</biblScope>
<biblScope unit="page" to="963">963</biblScope>
</imprint>
<idno type="ISSN">1351-5101</idno>
</series>
<idno type="istex">149E5B3B259D07A88201CEC980E15039BAEE6548</idno>
<idno type="DOI">10.1111/j.1468-1331.2005.01096.x</idno>
<idno type="ArticleID">ENE1096</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1351-5101</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (economics)</term>
<term>Depression (epidemiology)</term>
<term>Depression (etiology)</term>
<term>Dyskinesias (economics)</term>
<term>Dyskinesias (etiology)</term>
<term>Dyskinesias (psychology)</term>
<term>Europe</term>
<term>Female</term>
<term>Health Care Costs</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (economics)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson's disease</term>
<term>Quality of Life</term>
<term>dyskinesias</term>
<term>health care costs</term>
<term>quality of life</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Europe</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Dyskinesias</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Depression</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Depression</term>
<term>Dyskinesias</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Dyskinesias</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Activities of Daily Living</term>
<term>Aged</term>
<term>Female</term>
<term>Health Care Costs</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Quality of Life</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The treatment of Parkinson's disease (PD) with l‐DOPA leads to involuntary movements (dyskinesias). This 6‐month observational study in three European countries in PD patients with various degrees of motor complications examined the effects of dyskinesias on the quality of life (QoL) of patients and health care costs. Retrospective and prospective health economic data were collected, and QoL of patients was measured using the Short Form‐36 (SF‐36) and the PD Quality of Life (PDQL) Scale. Regression analysis was used to estimate the adjusted effects of dyskinesias on QoL and costs, whilst accounting for the potentially confounding effects of disease progression, motor fluctuations and country. Increasing dyskinesia scores on either the Unified PD Rating Scale or the Goetz Dyskinesia Rating Scale were associated with significant reductions in QoL scores on the SF‐36 and PDQL Scale. Increasing dyskinesia severity was also associated with increased depression scores on the Montgomery–Asberg Depression Rating Scale along with significant increases in health care costs. The effects of dyskinesia on QoL, depression and costs decreased but remained significant after adjustment for the confounding effects of disease progression and motor fluctuations. In conclusion, dyskinesias may adversely affect QoL and increase health care costs in patients with PD. Future studies should evaluate the potentially beneficial effects in terms of QoL and health care costs of strategies to delay the onset of, or the treatment of, dyskinesias.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>France</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Midlands de l'Ouest</li>
<li>Région Bretagne</li>
<li>Île-de-France</li>
</region>
<settlement><li>Birmingham</li>
<li>Paris</li>
<li>Vannes</li>
</settlement>
<orgName><li>Université de Birmingham</li>
</orgName>
</list>
<tree><country name="France"><noRegion><name sortKey="Pechevis, M" sort="Pechevis, M" uniqKey="Pechevis M" first="M." last="Péchevis">M. Péchevis</name>
</noRegion>
<name sortKey="Berdeaux, G" sort="Berdeaux, G" uniqKey="Berdeaux G" first="G." last="Berdeaux">G. Berdeaux</name>
<name sortKey="Deschaseaux Oinet, C" sort="Deschaseaux Oinet, C" uniqKey="Deschaseaux Oinet C" first="C." last="Deschaseaux-Voinet">C. Deschaseaux-Voinet</name>
<name sortKey="Khoshnood, B" sort="Khoshnood, B" uniqKey="Khoshnood B" first="B." last="Khoshnood">B. Khoshnood</name>
<name sortKey="Ziegler, M" sort="Ziegler, M" uniqKey="Ziegler M" first="M." last="Ziegler">M. Ziegler</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Clarke, C E" sort="Clarke, C E" uniqKey="Clarke C" first="C. E." last="Clarke">C. E. Clarke</name>
</region>
</country>
<country name="Allemagne"><noRegion><name sortKey="Vieregge, P" sort="Vieregge, P" uniqKey="Vieregge P" first="P." last="Vieregge">P. Vieregge</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:149E5B3B259D07A88201CEC980E15039BAEE6548 |texte= Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |